New Virus-Like particle COVID vaccine enters first human tests
NCT ID NCT04839146
First seen Feb 20, 2026 · Last updated Jun 21, 2026 · Updated 17 times
Summary
This early-stage trial tested a new COVID-19 vaccine called ABNCoV2 in 45 healthy adults who had never had COVID-19. The vaccine uses a virus-like particle to train the immune system, and some doses included an adjuvant to boost response. The main goals were to check safety and measure antibody levels two weeks after the first shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Radboud univserity medical center
Nijmegen, Gelderland, 6525GA, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABNCoV2 vaccine (virus-like particle with or without MF59 adjuvant)
What this could lead to
If successful, this could lead to a new type of COVID-19 vaccine that may offer strong protection with fewer side effects.
What could go wrong
This is a very early Phase 1 trial with only 45 people, so safety and immune response are still uncertain. The vaccine may not work as hoped in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.